HALO HALOZYME THERAPEUTICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, HALOZYME THERAPEUTICS INC reported revenue of $481M (up 47.7% from a year earlier), net income of $230M and diluted EPS of $1.90; over the last four quarters revenue was $1.66B and net income $414M; for the fiscal year ended December 2025 revenue was $1.40B, up 37.6% on the year before.

HALO annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $1.40B, gross profit n/a, operating income $469M, net income $317M (margin 22.7%), EPS $2.56
• Fiscal year ended Dec 2024: revenue $1.02B, gross profit n/a, operating income $551M, net income $444M (margin 43.7%), EPS $3.43
• Fiscal year ended Dec 2023: revenue $829M, gross profit n/a, operating income $338M, net income $282M (margin 34.0%), EPS $2.10
• Fiscal year ended Dec 2022: revenue $660M, gross profit n/a, operating income $268M, net income $202M (margin 30.6%), EPS $1.44
• Fiscal year ended Dec 2021: revenue $443M, gross profit n/a, operating income $276M, net income $403M (margin 90.8%), EPS $2.74

HALO quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $481M (up 47.7% year over year), net income $230M, EPS $1.90
• Quarter ended Mar 31, 2026: revenue $377M (up 42.2% year over year), net income $150M, EPS $1.22
• Quarter ended Dec 31, 2025 (from the annual report): revenue $452M (up 51.6% year over year), net income −$142M, EPS −$1.13
• Quarter ended Sep 30, 2025: revenue $354M (up 22.1% year over year), net income $175M, EPS $1.43
• Quarter ended Jun 30, 2025: revenue $326M (up 40.8% year over year), net income $165M, EPS $1.33
• Quarter ended Mar 31, 2025: revenue $265M (up 35.2% year over year), net income $118M, EPS $0.93
• Quarter ended Dec 31, 2024 (from the annual report): revenue $298M (up 29.5% year over year), net income $137M, EPS $1.06
• Quarter ended Sep 30, 2024: revenue $290M (up 34.3% year over year), net income $137M, EPS $1.05
• Quarter ended Jun 30, 2024: revenue $231M (up 4.7% year over year), net income $93.2M, EPS $0.72
• Quarter ended Mar 31, 2024: revenue $196M (up 20.8% year over year), net income $76.8M, EPS $0.60
• Quarter ended Dec 31, 2023 (from the annual report): revenue $230M (up 26.7% year over year), net income $85.4M, EPS $0.64
• Quarter ended Sep 30, 2023: revenue $216M (up 3.4% year over year), net income $81.8M, EPS $0.61
• Quarter ended Jun 30, 2023: revenue $221M (up 45.1% year over year), net income $74.8M, EPS $0.56
• Quarter ended Mar 31, 2023: revenue $162M (up 38.3% year over year), net income $39.6M, EPS $0.29
• Quarter ended Dec 31, 2022 (from the annual report): revenue $181M (up 77.9% year over year), net income $57.7M, EPS $0.41
• Quarter ended Sep 30, 2022: revenue $209M (up 80.4% year over year), net income $61.6M, EPS $0.44
• Quarter ended Jun 30, 2022: revenue $152M (up 11.7% year over year), net income $22.7M, EPS $0.16
• Quarter ended Mar 31, 2022: revenue $117M (up 31.7% year over year), net income $60.1M, EPS $0.43
• Quarter ended Dec 31, 2021 (from the annual report): revenue $102M, net income $66.8M, EPS $0.45
• Quarter ended Sep 30, 2021: revenue $116M, net income $217M, EPS $1.48

HALO cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $652M, share buybacks $342M
• Fiscal year ended Dec 2024: operating cash flow $479M, share buybacks $250M
• Fiscal year ended Dec 2023: operating cash flow $389M, share buybacks $402M
• Fiscal year ended Dec 2022: operating cash flow $240M, share buybacks $200M
• Fiscal year ended Dec 2021: operating cash flow $299M, share buybacks $350M

HALO balance sheet

• Jun 30, 2026: cash $163M, total assets $2.58B, total liabilities $2.43B, shareholders' equity $144M, long-term debt $1.94B
• Mar 31, 2026: cash $310M, total assets $2.67B, total liabilities $2.45B, shareholders' equity $220M, long-term debt $1.94B
• Dec 31, 2025: cash $134M, total assets $2.53B, total liabilities $2.48B, shareholders' equity $48.8M, long-term debt $2.14B
• Sep 30, 2025: cash $420M, total assets $2.22B, total liabilities $1.72B, shareholders' equity $504M, long-term debt $800M
• Jun 30, 2025: cash $61.9M, total assets $2.05B, total liabilities $1.72B, shareholders' equity $333M, long-term debt $1.51B
• Mar 31, 2025: cash $176M, total assets $2.20B, total liabilities $1.71B, shareholders' equity $482M, long-term debt $1.51B
• Dec 31, 2024: cash $116M, total assets $2.06B, total liabilities $1.70B, shareholders' equity $364M, long-term debt $1.51B
• Sep 30, 2024: cash $154M, total assets $2.12B, total liabilities $1.67B, shareholders' equity $453M, long-term debt $1.50B

What is HALO's revenue?

HALOZYME THERAPEUTICS INC reported $1.66B of revenue over its last four quarters, through June 30, 2026.

Is HALO profitable?

Yes. HALOZYME THERAPEUTICS INC earned $414M over the last four quarters.

What is HALO's EPS?

Diluted earnings per share over the last four quarters were $3.42; $1.90 in the latest quarter.

HALO ownership and insider trades · All stocks